Log in

Relevant bibliographies by topics / HDS / Journal articles

To see the other types of publications on this topic, follow the link: HDS.

Journal articles on the topic 'HDS'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'HDS.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Carrado, K. A., J. H. Kim, C. S. Song, N. Castagnola, C. L. Marshall, and M. M. Schwartz. "HDS and deep HDS activity of CoMoS-mesostructured clay catalysts." Catalysis Today 116, no. 4 (September 2006): 478–84. http://dx.doi.org/10.1016/j.cattod.2006.06.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

LEDOUX, M. "Correlation between low-pressure thiophene HDS and high-pressure dibenzothiophene HDS." Journal of Catalysis 121, no. 1 (January 1990): 70–76. http://dx.doi.org/10.1016/0021-9517(90)90217-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ostrovskii, N. M., K. S. Gulyaev, O. A. Reutova, and A. N. Startsev. "Dynamics of active sites transformation in HDS-HDA catalyst." Canadian Journal of Chemical Engineering 74, no. 6 (December 1996): 935–40. http://dx.doi.org/10.1002/cjce.5450740617.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

TAKADA-HIDAI, Masahide. "Astronomy with the (Subaru)HDS." Journal of Advanced Science 5, no. 4 (1993): 99–104. http://dx.doi.org/10.2978/jsas.5.4_99.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

STARTSEV, ANATOLII N. "The Mechanism of HDS Catalysis." Catalysis Reviews 37, no. 3 (August 1995): 353–423. http://dx.doi.org/10.1080/01614949508006446.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Reshetyuk, Y. "CALIBRATION OF TERRESTRIAL LASER SCANNERS CALLIDUS 1.1, LEICA HDS 3000 AND LEICA HDS 2500." Survey Review 38, no. 302 (October 2006): 703–13. http://dx.doi.org/10.1179/sre.2006.38.302.703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bumgarner, R. E., D. J. Pauley, and S. G. Kukolich. "Microwave measurements on ArH2S, ArHDS and ArD2S complexes." Journal of Molecular Structure 190 (November 1988): 163–71. http://dx.doi.org/10.1016/0022-2860(88)80281-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Licea, Yordy E., Sandra L. Amaya, Adriana Echavarría, Jefferson Bettini, Jean G. Eon, Luz A. Palacio, and Arnaldo C. Faro. "Simultaneous tetralin HDA and dibenzothiophene HDS reactions on NiMo bulk sulphide catalysts obtained from mixed oxides." Catal. Sci. Technol. 4, no. 5 (2014): 1227–38. http://dx.doi.org/10.1039/c3cy00801k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Olivas, A., D. H. Galván, G. Alonso, and S. Fuentes. "Trimetallic NiMoW unsupported catalysts for HDS." Applied Catalysis A: General 352, no. 1-2 (January 15, 2009): 10–16. http://dx.doi.org/10.1016/j.apcata.2008.09.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

McKee, C. S. "The bimetallic bond. III. HDS catalysis." Applied Catalysis A: General 137, no. 1 (March 1996): N2—N3. http://dx.doi.org/10.1016/0926-860x(96)80069-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Fierro, J. L. G., R. Cuevas, J. Ramírez, and A. López Agudo. "Activity and Selectivity Trends of F-Modified NiMo Catalysts in Various Hydrotreating (HDS/HDS, HYD) Reactions." Bulletin des Sociétés Chimiques Belges 100, no. 11-12 (September 1, 2010): 945–52. http://dx.doi.org/10.1002/bscb.19911001120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Domínguez-Crespo, M. A., A. M. Torres-Huerta, L. Díaz-García, E. M. Arce-Estrada, and E. Ramírez-Meneses. "HDS, HDN and HDA activities of nickel–molybdenum catalysts supported on alumina." Fuel Processing Technology 89, no. 8 (August 2008): 788–96. http://dx.doi.org/10.1016/j.fuproc.2008.01.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Homma, Takehide, Michaël Echard, and Jacques Leglise. "Investigation of CoNiMo/Al2O3 catalysts: Relationship between H2S adsorption and HDS activity." Catalysis Today 106, no. 1-4 (October 2005): 238–42. http://dx.doi.org/10.1016/j.cattod.2005.07.187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Fernández-Sánchez, J. M., and W. F. Murphy. "Raman scattering cross sections and polarizability derivatives of H2S, D2S, and HDS." Journal of Molecular Spectroscopy 156, no. 2 (December 1992): 431–43. http://dx.doi.org/10.1016/0022-2852(92)90244-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Cowan, R., M. Høglin, H. Reinink, J. Jsebaert, and D. Chadwick. "Influence of ammonia on thiophene HDS at high pressures over noble metal catalysts for deep HDS applications." Catalysis Today 45, no. 1-4 (October 1998): 381–84. http://dx.doi.org/10.1016/s0920-5861(98)00269-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Ladetto, M., F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Liberati, M. Musso, A. Pulsoni, A. M. Gianni, and C. Tarella. "Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) has better EFS and PFS than R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: A multicenter randomized GITMO/IIL trial." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 7525. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7525.

Full text

Abstract:

7525 Background: HDS with ASCT is effective and feasible in FL at the multicenter level and suitable for Rituximab supplementation (R-HDS). This randomized trial compared R-HDS with Rituximab-supplemented CHOP (R-CHOP) in poor risk FL patients (pts) <60 yrs. Methods: Between 2000 and 2005, 136 pts have been randomized (68/arm). Eligibility required age-adjusted IPI ≥2 (125 pts) or, in the absence of this criterion, ≥3 IIL adverse factors (11 pts). Primary endpoint was EFS. Clinical features were: median age 50 yrs (22–60), stage III-IV 98%, elevated LDH 78%, bulky disease 66%, B symptoms 47%, extranodal disease (other than BM) 45%, ECOG PS >1 47%. R-HDS consisted of: i. 2 APO and 2 DHAP; ii. sequential administration of Etoposide 2g/sqm, 2 Rituximab, Cyclophosphamide 7 g/sqm with PBPC collection (in vivo-purged with 2 additional Rituximab); iii. Mitoxantrone (60 mg/sqm) + L-Pam (180 mg/sqm) followed by 5–8 × 106 CD34+ cells/kg. R-CHOP consisted of 6 CHOP courses followed by 4–6 doses of Rituximab. Cross-over was allowed. bcl-2/I gH-based minimal residual disease analysis was planned. Assessement was “intention to treat”-based. Results: Current data are updated at 31/5/05. Next closing date will be April 2006. The two arms were balanced. 68% patients concluded R-CHOP (failures were due to progression 29% and toxicity 3%) and 78% R-HDS (failures due to progression 9%, toxicity 5%, poor mobilization/refusal 8%). Toxic deaths were 4 (2 in each arm); in addition 1 gastric cancer and 1 AML occurred in the R-HDS arm. Progressions and non-responses were 31% with R-CHOP and 11% with R-HDS (p < 0.05) CRs were 58% and 87% respectively. Current median follow-up is 24 months. EFS and PFS at 24 months are 41% and 48% for R-CHOP and 66% and 75% for R-HDS (p < .001). At present OS is similar. Salvage treatment following R-CHOP is currently known in 22 pts: 16 received R-HDS, with 10 achieving CR. Molecular remission, (two PCR-neg BM samples at 6 months intervals), was observed in 54% of R-CHOP and 77% of R-HDS pts Conclusions: R-HDS induces more CRs and has better EFS and PFS than R-CHOP in this rare and aggressive population of high-risk FL patients. These results cannot be extrapolated to standard-risk pts. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

17

Portela, L., P. Grange, and B. Delmon. "Surface Characteristics and Selectivity of HDS Catalysts." Bulletin des Sociétés Chimiques Belges 100, no. 11-12 (September 1, 2010): 985–91. http://dx.doi.org/10.1002/bscb.19911001125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Dungey, Keenan E., M. David Curtis, and James E. Penner-Hahn. "Behavior of MoS2Intercalation Compounds in HDS Catalysis." Journal of Catalysis 175, no. 1 (April 1998): 129–34. http://dx.doi.org/10.1006/jcat.1998.1963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Halliday, James D., and Patrick E. Bindner. "Disproportionation of HDS in the liquid phase." Canadian Journal of Chemistry 63, no. 11 (November 1, 1985): 2821–23. http://dx.doi.org/10.1139/v85-471.

Full text

Abstract:

The deuteron–proton liquid phase isotopic disproportionation constant in hydrogen sulphide, K1, defined for the equilibrium[Formula: see text]has been measured at 25.7 °C. The value of K1 was 3.99 ± 0.11, based upon direct measurements of the concentrations of the three molecular species H2S, HDS, and D2S by 1H and 2H nuclear magnetic resonance spectroscopy (nmr) of carefully purified samples. This compares with the theoretical vapour phase isotopic distribution constant Kv = 3.92, calculated from ideal gas vapour phase isotopic partition function ratios (1, 2).

APA, Harvard, Vancouver, ISO, and other styles

20

Covian, Enrique, Miguel Casero, Marta Menéndez, and Antonio Bernardo. "Application of HDS techniques to bridge inspection." Nondestructive Testing and Evaluation 33, no. 3 (February 26, 2018): 301–14. http://dx.doi.org/10.1080/10589759.2018.1441411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Gheek, P., S. Suppan, J. Trawczyński, A. Hynaux, C. Sayag, and G. Djega-Mariadssou. "Carbon black composites—supports of HDS catalysts." Catalysis Today 119, no. 1-4 (January 2007): 19–22. http://dx.doi.org/10.1016/j.cattod.2006.08.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

BAUMGART, J. "Characteristics of laboratory-coked resid HDS catalyst." Journal of Catalysis 126, no. 2 (December 1990): 477–88. http://dx.doi.org/10.1016/0021-9517(90)90014-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Aoki, W. "The Subaru Telescope High Dispersion Spectrograph (HDS)." Astronomische Nachrichten 335, no. 1 (January 2014): 27–31. http://dx.doi.org/10.1002/asna.201312003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Parvin, Kheirollah, and Mohammad Zereshgi. "Analysing The law prisoners of War by the Islamic And Muslims Jurists’ Standpoint." Holy Defense Studies 6, no. 3 (November 1, 2020): 9–38. http://dx.doi.org/10.29252/hds.6.3.9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Kasahara, Seiji, Takehiro Shimizu, and Muneyoshi Yamada. "Inhibiting effects of H2S on HDS activity of CoMo-, NiMo-, and Mo/Al2O3." Catalysis Today 35, no. 1-2 (March 1997): 59–64. http://dx.doi.org/10.1016/s0920-5861(96)00143-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Bumgarner, R. E., D. J. Pauley, and S. G. Kukolich. "Microwave spectra and structure for SO2⋅⋅⋅H2S, SO2⋅⋅⋅HDS, and SO2⋅⋅⋅D2S complexes." Journal of Chemical Physics 87, no. 7 (October 1987): 3749–52. http://dx.doi.org/10.1063/1.452929.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Baldovino-Medrano, V. G., Sonia A. Giraldo, and Aristóbulo Centeno. "The functionalities of Pt/γ-Al2O3 catalysts in simultaneous HDS and HDA reactions." Fuel 87, no. 10-11 (August 2008): 1917–26. http://dx.doi.org/10.1016/j.fuel.2007.12.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bianchini, Claudio, M. Victoria Jiménez, Carlo Mealli, Andrea Meli, Simonetta Moneti, Véronique Patinec, and Francesco Vizza. "Like on Heterogeneous Hydrodesulfurization(HDS) Catalysts, the Homogeneous HDS of Benzo[b]thiophene Is Achived by the Concomitant Action of a Metal Promoter(Rh) and an Active HDS Component(W)." Angewandte Chemie International Edition in English 35, no. 15 (August 1996): 1706–8. http://dx.doi.org/10.1002/anie.199617061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Ladetto, Marco, Federica De Marco, Fabio Benedetti, Umberto Vitolo, Caterina Patti, Alessandro Rambaldi, Alessandro Pulsoni, et al. "Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage." Blood 111, no. 8 (April 15, 2008): 4004–13. http://dx.doi.org/10.1182/blood-2007-10-116749.

Full text

Abstract:

Abstract In this randomized multicenter study of 136 patients, 6 courses of CHOP (cyclo-phosphamide/doxorubicin/vincristine/prednisone) followed by rituximab (CHOP-R) were compared with rituximab-supplemented high-dose sequential chemotherapy with autografting (R-HDS) to assess the value of intensified chemo-therapy as a first-line treatment for high-risk follicular lymphoma (FL) after the introduction of monoclonal antibodies. The analysis was intention to treat with event-free survival (EFS) as the primary endpoint. Complete remission (CR) was 62% with CHOP-R and 85% with R-HDS (P < .001). At a median follow-up (MFU) of 51 months, the 4-year EFS was 28% and 61%, respectively (P < .001), with no difference in overall survival (OS). Molecular remission (MR) was achieved in 44% of CHOP-R and 80% of R-HDS patients (P < .001), and was the strongest independent outcome predictor. Patients relapsing after CHOP-R underwent salvage R-HDS in 71% of cases. Salvage R-HDS had an 85% CR rate and a 68% 3-year EFS (MFU, 30 months). We conclude that (1) achieving MR is critical for effective disease control, regardless of which treatment is used; (2) R-HDS ensures superior disease control and molecular outcome than CHOP-R, but no OS improvement; and (3) CHOP-R failures have a good outcome after salvage R-HDS, suggesting that relapsed/refractory FL could be the most appropriate setting for R-HDS–like treatments. This trial was registered at www.clinicaltrials.gov as no. NCT00435955.

APA, Harvard, Vancouver, ISO, and other styles

30

Wang, Jin-Zheng, Yongxing Lei, Yanmei Xiao, Xiang He, Jiubo Liang, Jishan Jiang, Shangzhi Dong, et al. "Uncovering the functional residues ofArabidopsisisoprenoid biosynthesis enzyme HDS." Proceedings of the National Academy of Sciences 117, no. 1 (December 26, 2019): 355–61. http://dx.doi.org/10.1073/pnas.1916434117.

Full text

Abstract:

The methylerythritol phosphate (MEP) pathway is responsible for producing isoprenoids, metabolites with essential functions in the bacterial kingdom and plastid-bearing organisms including plants and Apicomplexa. Additionally, the MEP-pathway intermediate methylerythritol cyclodiphosphate (MEcPP) serves as a plastid-to-nucleus retrograde signal. A suppressor screen of the high MEcPP accumulating mutant plant (ceh1) led to the isolation of 3 revertants (designatedRceh1–3) resulting from independent intragenic substitutions of conserved amino acids in the penultimate MEP-pathway enzyme, hydroxymethylbutenyl diphosphate synthase (HDS). The revertants accumulate varying MEcPP levels, lower than that ofceh1, and exhibit partial or full recovery of MEcPP-mediated phenotypes, including stunted growth and induced expression of stress response genes and the corresponding metabolites. Structural modeling of HDS and ligand docking spatially position the substituted residues at the MEcPP binding pocket and cofactor binding domain of the enzyme. Complementation assays confirm the role of these residues in suppressing theceh1mutant phenotypes, albeit to different degrees. In vitro enzyme assays of wild type and HDS variants exhibit differential activities and reveal an unanticipated mismatch between enzyme kinetics and the in vivo MEcPP levels in the correspondingRcehlines. Additional analyses attribute the mismatch, in part, to the abundance of the first and rate-limiting MEP-pathway enzyme, DXS, and further suggest MEcPP as a rheostat for abundance of the upstream enzyme instrumental in fine-tuning of the pathway flux. Collectively, this study identifies critical residues of a key MEP-pathway enzyme, HDS, valuable for synthetic engineering of isoprenoids, and as potential targets for rational design of antiinfective drugs.

APA, Harvard, Vancouver, ISO, and other styles

31

Ladetto, Marco, Federica De Marco, Fabio Benedetti, Umberto Vitolo, Caterina Patti, Alessandro Rambaldi, Alessandro Pulsoni, et al. "Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment." Blood 110, no. 11 (November 16, 2007): 20. http://dx.doi.org/10.1182/blood.v110.11.20.20.

Full text

Abstract:

Abstract Background. A randomised trial has been performed among several GITMO/IIL italian centers, comparing Rituximab-supplemented High-Dose Sequential Chemotherapy (R-HDS) and CHOP-R in high-risk FL <60 yrs. The updated results are here presented, after a median follow-up of 50 months. Patients (pts) and Methods. Eligibility was based on age-adjusted IPI >=2 (125 pts) or on the IIL score >=3 (11 pts). 136 pts were randomized (68/arm). Main clinical features were: median age 51 yrs. (22–59), stage III–IV 98%, elevated LDH 59%, bulky disease 56%, B symptoms 47%, extranodal disease other than bone marrow (BM) 31%, PS >1 (ECOG) 60%. Both R-HDS and CHOP-R have been already described (Ladetto et al ASH 2005, Rambaldi et al Blood 2000). Cross-over was allowed for pts failing CHOP-R. Centralized minimal residual disease (MRD) analysis with the bcl-2/IgH was performed on BM samples. Analysis was intention to treat. Results. Early toxic deaths were 5 (2 in CHOP-R, 3 in R-HDS); CR rates were 61% with CHOP-R and 85% with R-HDS (p<0.001). At four years EFS and PFS are 32% and 33% for CHOP-R, and 64% and 76% for R-HDS (p<0.001). Despite a better EFS, OS is not different in the two arms (82% CHOP-R and 79% R-HDS). One fatal secondary myelodysplastic syndrome occurred in the CHOP-R arm and five (three fatal) in the R-HDS arm with a cumulative incidence at four years of 3.3% and 7.9% respectively. A stable molecular remission (MR) (achieved in 44% of CHOP-R and 80% of R-HDS pts) (p<0,001) was associated with an improved PFS (22% vs 78% at four years) (p<0,001) and proved the strongest outcome predictor for EFS and PFS by multivariate analysis (Hazard Ratio: 3.98 and 3.83, respectively). Interestingly, the PFS of PCR-negative pts was similar in the two arms, as well as that of PCR-positive pts. Of 39 patients with relapsed or refractory disease after CHOP-R 28 were crossed to R-HDS (71%). Reasons for not undergoing cross-over were: limited relapse in 4, co-morbidities in 2, refusal in 2, other causes in 3. Overall CR rate for second line treatment after CHOP-R failure was 77% (86% with R-HDS and 54% with other therapy). At a median follow-up of 30 months the three-year EFS of patients undergoing salvage R-HDS is 70%. Conclusions: In high-risk FL: a) first-line R-HDS ensures better EFS and PFS and superior molecular outcome than CHOP-R; b) pts undergoing salvage R-HDS have an excellent clinical outcome; c) the long-term OS is markedly improved compared to the pre-rituximab era, with no difference between CHOP-R and R-HDS; d) both the high efficacy as salvage treatment and the potential side effects suggest that the ideal positioning of R-HDS-like treatments is beyond first line treatment, for relapsed or refractory disease; e) a PCR-negative status is the most important prognostic factor regardless of treatment received and pts with persistent PCR-positivity might potentially be considered for specific experimental intervention.

APA, Harvard, Vancouver, ISO, and other styles

32

Prokešová, A., V. Tukač, and M. Zbuzek. "Hydrodynamics characteristics of HDS trickle bed test reactor." Procedia Engineering 42 (2012): 885–91. http://dx.doi.org/10.1016/j.proeng.2012.07.481.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Noguchi, Kunio, Wako Aoki, Satoshi Kawanomoto, Hiroyasu Ando, Satoshi Honda, Hideyuki Izumiura, Eiji Kambe, et al. "High Dispersion Spectrograph (HDS) for the Subaru Telescope." Publications of the Astronomical Society of Japan 54, no. 6 (December 25, 2002): 855–64. http://dx.doi.org/10.1093/pasj/54.6.855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Ho, Teh C. "Property–reactivity correlation for HDS of middle distillates." Applied Catalysis A: General 244, no. 1 (May 2003): 115–28. http://dx.doi.org/10.1016/s0926-860x(02)00572-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Yamada, Muneyoshi, Kohichi Segawa, and Yasuo Ohtsuka. "HDS and HDN catalysis for super-clean fuels." Catalysis Today 39, no. 1-2 (December 1997): 1. http://dx.doi.org/10.1016/s0920-5861(97)81569-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Hada, Kenichiro, Masatoshi Nagai, and Shinzo Omi. "Characterization and HDS Activity of Cobalt Molybdenum Nitrides." Journal of Physical Chemistry B 105, no. 19 (May 2001): 4084–93. http://dx.doi.org/10.1021/jp002133c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Sato, Toshio, Shuzo Kanzaki, Yuji Yoshimura, Hiromichi Shimada, Nobuyuki Matubayashi, Yasuo Shibazaki, and Akio Nishijima. "New Type of Crystalline Support for HDS Catalyst." Chemistry Letters 17, no. 2 (February 5, 1988): 315–16. http://dx.doi.org/10.1246/cl.1988.315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Chen, Jinwen, Hong Yang, and Zbigniew Ring. "HDS kinetics study of dibenzothiophenic compounds in LCO." Catalysis Today 98, no. 1-2 (November 2004): 227–33. http://dx.doi.org/10.1016/j.cattod.2004.07.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Ho, Teh C. "Deep HDS of diesel fuel: chemistry and catalysis." Catalysis Today 98, no. 1-2 (November 2004): 3–18. http://dx.doi.org/10.1016/j.cattod.2004.07.048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

LINDNER, J. "Chemisorption studies of promoted solid-state HDS catalysts." Journal of Catalysis 135, no. 2 (June 1992): 427–33. http://dx.doi.org/10.1016/0021-9517(92)90044-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

PIRIE, R. S., G. McLACHLAN, and B. C. McGORUM. "Evaluation of nebulised hay dust suspensions (HDS) for the diagnosis and investigation of heaves. 1: Preparation and composition of HDS." Equine Veterinary Journal 34, no. 4 (January 5, 2010): 332–36. http://dx.doi.org/10.2746/042516402776249092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

PIRIE, R. S., P. M. DIXON, and B. C. McGORUM. "Evaluation of nebulised hay dust suspensions (HDS) for the diagnosis and investigation of heaves. 3: Effect of fractionation of HDS." Equine Veterinary Journal 34, no. 4 (January 5, 2010): 343–47. http://dx.doi.org/10.2746/042516402776249236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Ladetto, Marco, Irene Ricca, Fabio Benedetti, Umberto Vitolo, Caterina Patti, Alessandro Rambaldi, Anna Marina Liberati, et al. "Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial." Blood 106, no. 11 (November 16, 2005): 675. http://dx.doi.org/10.1182/blood.v106.11.675.675.

Full text

Abstract:

Abstract Introduction. HDS with autografting has proved to be effective (Corradini et al, J Clin Oncol 2004) and feasible at the multicenter level in FL (Ladetto et al, Blood 2002); in addition, it can be successfully combined with Rituximab (R-HDS) (Magni et al, Blood 2000). Aim of this trial was to compare R-HDS with Rituximab-supplemented CHOP (R-CHOP) in poor risk FL patients (pts) younger than 60 years. Patients and methods. Between January 2000 and March 2005, 136 patients have been randomized (68 in each arm). Patients were stratified according to histology (grade I or II 101, grade III 35). Patients were eligible if they had an age-adjusted IPI ≥2 (125 pts) or, in the absence of this criterion if they had three or more adverse parameters according to the Italian Lymphoma Intergroup score (11 pts). Clinical features were: median age 50 yrs. (22–60), stage III-IV 98%, elevated LDH 78%, bulky disease 66%, B symptoms 47%, extranodal disease (other than BM) 45%, leukemic disease 11%, ECOG PS >1 47%. R-HDS consisted of: i. 2 APO and 2 DHAP courses; ii. sequential administration of Etoposide (2 g/sqm), 2 Rituximab, Cyclophosphamide (Cy) (7g/sqm) with PBPC collection (in vivo-purged with two Rituximab on day 1 and 11 post Cy); iii. Mitoxantrone (60mg/sqm) + L-Pam (180mg/sqm) with autografting (5–8x106 CD34+ cells/kg). R-CHOP consisted of 6 CHOP courses followed by 4–6 doses of Rituximab as originally reported (Rambaldi et al, Blood 2002). Cross-over was allowed for patients failing R-CHOP. Minimal residual disease analysis with the bcl-2/IgH was planned on BM cells. Patients were assessed on an “intention to treat” basis. Results. The two treatments arms were well balanced for all the previously described clinical parameters. 68% patients were able to conclude R-CHOP (failure due to progression 29% and toxicity 3%) and 78% R-HDS (failure due to progression 9%, toxicity 5%, poor mobilization 4 %, refusal 4%). Toxic deaths were 4 (2 in each arms); in addition 1 gastric cancer and 1 AML occurred in the R-HDS group. Progressions and non-responders were 35% in the R-CHOP arm and 13% in the R-HDS (p<0.05) with 53% and 82% CR rates, respectively. Current median follow-up is 24 months. Event-free survival (EFS) at 24 months is 41% for the R-CHOP arm and 66% for the R-HDS arm (p< .001). At present there is no difference in terms of OS. We currently have data on salvage treatment in 22 patients failing R-CHOP: 16 of them were treated with R-HDS, with 10 achieving CR. A molecular marker was available in 72% of patients. PCR results at follow-up are available in 27 patients. Molecular remission, defined as two PCR-negative BM samples taken at six months intervals, was observed in 54% of R-CHOP and 77% of R-HDS patients. Conclusions. R-HDS induces a greater number of CR and ensures a better EFS compared to R-CHOP in this rare and extremely aggressive population of high-risk FL patients. It is unknown if these results reflect a peculiar behaviour of high-risk patients or can be relevant for all younger FCL patients with advanced disease requiring cytoreductive treatments.

APA, Harvard, Vancouver, ISO, and other styles

44

Ding, Lianhui, Ying Zheng, Zisheng Zhang, Zbigniew Ring, and Jinwen Chen. "HDS, HDN, HDA, and hydrocracking of model compounds over Mo-Ni catalysts with various acidities." Applied Catalysis A: General 319 (March 2007): 25–37. http://dx.doi.org/10.1016/j.apcata.2006.11.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Chen, Jinwen, and Zbigniew Ring. "HDS reactivities of dibenzothiophenic compounds in a LC-finer LGO and H2S/NH3 inhibition effect." Fuel 83, no. 3 (February 2004): 305–13. http://dx.doi.org/10.1016/j.fuel.2003.08.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Srinivas, Bhadri, Srikanth Karthik, and B. Sankararao. "Optimization of Trickle-Bed Reactors (TBRs) for Hydrodesulfurization (HDS) and Hydrodearomatization (HDA) of Diesel using Single and Multiple Objectives." Chemical Product and Process Modeling 8, no. 2 (September 6, 2013): 93–106. http://dx.doi.org/10.1515/cppm-2013-0023.

Full text

Abstract:

Abstract This article describes the formulation, solution and analysis of two single-objective optimization and one multi-objective optimization (MOO) problems on trickle-bed reactors (TBRs) involving hydrodesulfurization (HDS) and hydrodearomatization (HDA). The model used by Chowdhury et al. (AIChE J 2002;48:26) for TBR involving HDS and HDA is used in this study, to solve these optimization problems. The correctness of algorithm and the numerical procedure used in this study to solve the model equations are validated with the results of Chowdhury et al. (AIChE J 2002;48:26), before the model is used for optimization. Objective functions chosen in our optimization studies are minimization of sulfur concentration and maximization of total conversion of aromatics at the exit of TBR. Decision variables considered are reactor temperature, reactor pressure and liquid hourly space velocity (LHSV). Two single-objective optimization and one MOO problems are formulated and solved using simple genetic algorithm (SGA) and NSGA-II, respectively, to obtain the optimal values of reactor operating conditions. Pareto set for the MOO problem is generated which show that conflicting nature of the objective functions. Specifically, we have shown that the simultaneous minimization of exit sulfur and maximization of aromatics removal conflict each other in hydrotreating.

APA, Harvard, Vancouver, ISO, and other styles

47

UCHIYAMA, Hisashi, and Ichiro FUKUMOTO. "Relativity between HDS-R and POMS in healthy elderly." Japanese journal of ergonomics 41, Supplement (2005): 316–17. http://dx.doi.org/10.5100/jje.41.supplement_316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Suarez, Lucia, D. Warichet, and Yvan Houbaert. "Galvanized Coatings Produced in a Hot Dip Simulator (HDS)." Defect and Diffusion Forum 297-301 (April 2010): 1048–52. http://dx.doi.org/10.4028/www.scientific.net/ddf.297-301.1048.

Full text

Abstract:

Hot dip galvanizing has proven to provide excellent protection against corrosion of steel for a wide range of applications. Coatings of Zn-Al alloys on steel sheet give a high corrosion resistance due to the corrosion prevention by zinc and the passivation by Al. Many important industrial processing steps require a reliable procedure for process verification. Verification on production or pilot lines is neither economical nor efficient. Simulators for the HDP (Hot Dip Process) allow laboratory scale simulations of the (hot dip) coating and of the consequent annealing processes occurring in industrial production lines, serving for process and product improvement and development. To improve and further develop the production and the final coating properties, hot dipping experiments are performed in a HDP simulator using different substrates, bath compositions and hot dipping parameters. The results obtained by these simulations are transferable to the production process of real continuous galvanizing lines. Important industrial steps of the process can be simulated in the HDPS with a high variability of parameters.

APA, Harvard, Vancouver, ISO, and other styles

49

Curtis, M. David, James E. Penner-Hahn, Johannes Schwank, Oswaldo Baralt, Daniel J. McCabe, Levi Thompson, and Geoffrey Waldo. "Syngas and HDS catalysts derived from sulphido bimetallic clusters." Polyhedron 7, no. 22-23 (January 1988): 2411–20. http://dx.doi.org/10.1016/s0277-5387(00)86361-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Scheffer, B., E. M. van Oers, P. Arnoldy, V. H. J. de Beer, and J. A. Moulijn. "Sulfidability and HDS activity of Co-Mo/Al2O3 catalysts." Applied Catalysis 25, no. 1-2 (August 1986): 303–11. http://dx.doi.org/10.1016/s0166-9834(00)81248-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!